一分钟看懂
这是一项关于癌的II 期研究，登记的药物或干预包括Niraparib，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Niraparib · II 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为女性，年龄18岁至75岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Cancer Hospital · 北京
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. The written informed consent form shall be signed before proceeding with any study-related procedure.
- 2. Participants shall be a female, aged 18 years or older.
- 3. Histologically confirmed primary high-grade epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma。
- 4. FIGO staging is Stage III or IV.
- 5. Patients who have undergone primary tumor reductive surgery or intermittent tumor reductive surgery (patients who have used neoadjuvant therapy), regardless of postoperative residual lesion status
- 6. Participants must have received, prior to enrollment, a minimum of 2 cycles of bevacizumab in combination with platinum-based chemotherapy.
- 7. Participants must have completed front-line, platinum-based chemotherapy with CR, PR, or NED assessed by RECIST v1.1.
- 8. Participant must have either CA-125 in the normal range or CA-125 decrease by more than 90% during front-line therapy that is stable for at least 7 days (ie, no increase \> 15% from nadir).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06141265；登记信息更新于 2026-10-01；本站同步于 2026-10-08。